These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15749164)

  • 21. Technical foundations and pitfalls of clinical fMRI.
    Jezzard P; Song AW
    Neuroimage; 1996 Dec; 4(3 Pt 3):S63-75. PubMed ID: 9345530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid three-dimensional functional magnetic resonance imaging of the initial negative BOLD response.
    Lindquist MA; Zhang CH; Glover G; Shepp L
    J Magn Reson; 2008 Mar; 191(1):100-11. PubMed ID: 18207441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of susceptibility weighted imaging in functional MRI.
    Haacke EM; Ye Y
    Neuroimage; 2012 Aug; 62(2):923-9. PubMed ID: 22245649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of real-time fMRI.
    deCharms RC
    Nat Rev Neurosci; 2008 Sep; 9(9):720-9. PubMed ID: 18714327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
    Thilmann O; Larsson EM; Björkman-Burtscher IM; Ståhlberg F; Wirestam R
    J Magn Reson Imaging; 2005 Nov; 22(5):597-604. PubMed ID: 16200539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular magnetic resonance imaging with targeted contrast agents.
    Artemov D
    J Cell Biochem; 2003 Oct; 90(3):518-24. PubMed ID: 14523986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping of functional brain activity in freely behaving rats during voluntary running using manganese-enhanced MRI: implication for longitudinal studies.
    Eschenko O; Canals S; Simanova I; Beyerlein M; Murayama Y; Logothetis NK
    Neuroimage; 2010 Feb; 49(3):2544-55. PubMed ID: 19896539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo oxygen detection using exogenous hemoglobin as a contrast agent in magnetic resonance microscopy.
    Sun PZ; Schoening ZB; Jasanoff A
    Magn Reson Med; 2003 Apr; 49(4):609-14. PubMed ID: 12652529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resampling fMRI time series.
    Friman O; Westin CF
    Neuroimage; 2005 Apr; 25(3):859-67. PubMed ID: 15808986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular imaging with targeted contrast agents.
    Makowski MR; Wiethoff AJ; Jansen CH; Botnar RM
    Top Magn Reson Imaging; 2009 Aug; 20(4):247-59. PubMed ID: 20805735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contrast agents in magnetic resonance imaging: development and problems].
    Xu YK
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep; 22(9):769-71. PubMed ID: 12297425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain mapping with high-resolution FMRI technology.
    Liu N
    Methods Mol Biol; 2007; 401():195-210. PubMed ID: 18368368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo imaging of inhibitory, GABAergic neurons by MRI.
    Aswendt M; Gianolio E; Pariani G; Napolitano R; Fedeli F; Himmelreich U; Aime S; Hoehn M
    Neuroimage; 2012 Sep; 62(3):1685-93. PubMed ID: 22609794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surface-based functional magnetic resonance imaging analysis of partial brain echo planar imaging data at 1.5 T.
    Jo HJ; Lee JM; Kim JH; Choi CH; Kang DH; Kwon JS; Kim SI
    Magn Reson Imaging; 2009 Jun; 27(5):691-700. PubMed ID: 19036544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications.
    Aime S; Castelli DD; Crich SG; Gianolio E; Terreno E
    Acc Chem Res; 2009 Jul; 42(7):822-31. PubMed ID: 19534516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiresolution data acquisition and detection in functional MRI.
    Yoo SS; Guttmann CR; Panych LP
    Neuroimage; 2001 Dec; 14(6):1476-85. PubMed ID: 11707104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the use of caffeine as a contrast booster for BOLD fMRI studies.
    Mulderink TA; Gitelman DR; Mesulam MM; Parrish TB
    Neuroimage; 2002 Jan; 15(1):37-44. PubMed ID: 11771972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A statistical fMRI model for differential T2* contrast incorporating T1 and T2* of gray matter.
    Karaman MM; Bruce IP; Rowe DB
    Magn Reson Imaging; 2014 Jan; 32(1):9-27. PubMed ID: 24183567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of EEG source imaging and fMRI during continuous viewing of natural movies.
    Whittingstall K; Bartels A; Singh V; Kwon S; Logothetis NK
    Magn Reson Imaging; 2010 Oct; 28(8):1135-42. PubMed ID: 20579829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for sensing neurotransmitters with responsive MRI contrast agents.
    Angelovski G; Tóth É
    Chem Soc Rev; 2017 Jan; 46(2):324-336. PubMed ID: 28059423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.